Brief: Conmed Corp - Announces Exit From Gastroenterology Product Lines
05/12/2025 13:01
Dec 5 (Reuters) - Conmed Corp CNMD.N: CONMED CORP - ANNOUNCES EXIT FROM GASTROENTEROLOGY PRODUCT LINES CONMED CORP - COMPANY EXPECTS EPS DILUTION OF $0.45-$0.55 IN 2026 CONMED CORP - REAFFIRMS 2025 REVENUE AND EPS GUIDANCE CONMED CORP: FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED Source text: ID:nBw9vdjPna Further company coverage: CNMD.N ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Conmed
See all newsBrief: Conmed Enters Agreements To Repurchase 2.25% Convertible Senior Notes Due 2027 On June 3 - SEC Filing
Brief: Conmed Enters First Omnibus Amendment And Increased Facility Activation Notice On May 27, 2026 - SEC Filing
Brief: Conmed Corporation Appoints Celine Martin And Jeff Mirviss To Its Board Of Directors
Medical device maker Conmed raises 2026 organic rev outlook, reaffirms EPS guidance
Brief: Micro-Tech Endoscopy To Acquire Duraclip, Precisor, And Optibite Product Lines From CONMED